Latest Drospirenone Stories

According to the US Drug Watchdog, "We are now offering to help women who used the birth control pills called Yaz, Yasmin, and Ocella, and then had a heart attack, blood clot, or other very serious health side affects get to the best attorneys." According to the New York Times, "In September of 2009, the US FDA released a warning letter sent to Bayer Pharmaceuticals over Yaz & Yasmin. The letter indicates that the drug maker hid out-of-specification test results for key...

(Ivanhoe Newswire) -- A 15-year Danish historical cohort study was done to see how hormonal contraception can cause thrombotic stroke (blood clotting inside a brain artery) and myocardial infarction (heart attack). In this study, 1,626,158 non-pregnant women from the ages of 15 to 49 years old were observed. During the study 3,311 thrombotic strokes and 1,725 myocardial infarctions occurred. The current use of oral contraceptive that included ethinyl estradiol (bio-active estrogen) at a...

According to court documents, on May 15th 2012, a Massachusetts woman, Janel Mahon, filed a lawsuit in Illinois Southern District Court (case no. 3:2012cv10881) alleging she suffered blood clots leading to a pulmonary embolism from Yaz. Yasmin, which was approved by the FDA in 2001, and its sister drug Yaz, which was approved in 2006, are oral contraceptives that combine estrogen and a fourth generation progestin, drospirenone, to prevent pregnancy. Yaz and Yasmin are manufactured by Bayer...

New video and 24/7 hotline available to a nswer questions about the 2012 Yaz, Beyaz, Ocella, Yasmin and Ocella Settlement. (800) 929-0287 New York, NY (PRWEB) June 01, 2012 Lawyers are standing by to answer all your questions about the 2012 Yaz, Yasmin, Ocella, Beyaz and Gianvi settlement. The phone number at (800) 929-0287 is for women who sustained a blood clot from one of the above products and are not currently represented by counsel. Thousands of women were allegedly injured by...

CRESSKILL, N.J., May 2, 2012 /PRNewswire/ -- Deadlines for lawsuits over side effects of the birth control drugs Yaz and Yasmin have been moved back another 90 days, the third time deadlines have been delayed this year. The extension by Chief Judge David R. Herndon, of the U.S. District Court for the Southern District of Illinois, allows settlement negotiations to continue between Bayer and lawyers for the more than 11,500 lawsuits that have been lodged against the drugs'...

The US Drug Watchdog is now warning that with a very poorly publicized possible settlement for women, who used the birth control pills called Yaz, Yasmin, or the generic version called Ocella, and then suffered a heart attack, a stroke, or a pulmonary embolism, time might be running out to get a settlement. As a background according to the September 17th 2009 edition of the New York Times, "The FDA released a warning letter sent in September to Bayer Pharmaceuticals over Yaz &...

The US Food and Drug Administration (FDA) has begun to add information to labels of popular birth control medications to warn about the increased risk of blood clots. Bayer AG’s “Yaz” or Yasmin is one of the medications receiving the new label, though all common types of birth control pills increase a woman’s risk of potentially fatal blood clots. The FDA is following up new studies with these labels, saying certain forms of birth control like Yaz show an even higher increase...

WAYNE, N.J., April 10, 2012 /PRNewswire/ -- In agreement with the U.S. Food and Drug Administration (FDA), Bayer HealthCare Pharmaceuticals Inc. today announced that it has updated the labels for its drospirenone-containing combination oral contraceptives (COCs) in the United States. The updated labels include additional information from recently published studies evaluating the risk of venous thromboembolism (blood clots) in women taking drsp-containing COCs. Specifically, the new...

In March 2012, Bayer Healthcare reported that it had reached agreements, without admission of liability, to settle the claims of approximately 70 plaintiffs on Yasmin/Yaz lawsuits in the U.S. at terms and conditions which Bayer views to be reasonable. Yasmin, which was approved by the FDA in 2001, and Yaz, which was approved in 2006, are oral contraceptives that combine estrogen and a fourth generation progestin, drospirenone, to prevent pregnancy. They are also used to treat premenstrual...

WAYNE, N.J, Feb. 29, 2012 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a lower dose formulation of ANGELIQ(® ) (drospirenone and estradiol) tablets to treat moderate to severe vasomotor symptoms due to menopause in women who have a uterus. The new formulation contains 0.25 mg drospirenone (drsp)/0.5 mg estradiol (E2) and will be available in the U.S. by prescription shortly. The previously...